Rubius Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Rubius Therapeutics

06/08/2021 15:25

* Rubius Therapeutics Inc  RUBY.OQ   RUBY.O  is expected to show
a no change in quarterly revenue when it reports results on
August 9. 
​* Refinitiv's mean analyst estimate for Rubius Therapeutics Inc
is for a loss of 49 cents per share. For the same quarter last
year, the company reported a loss of 47 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $32​, about 30.9% above​ its last closing
price of $22.10. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.53       -0.52      -0.51     Beat    1.3
 Dec. 31 2020  -0.52       -0.49      -0.50     Missed  -1
 Sep. 30 2020  -0.49       -0.49      -0.51     Missed  -3.4​
 Jun. 30 2020  -0.50       -0.50      -0.47     Beat    6.5
 Mar.          -0.55​      -0.56      -0.60     Missed  -8​
 31​ 2020​                                              
 Dec. 31 2019  -0.63       -0.60      -0.56     Beat    7​
 Sep. 30 2019  -0.55       -0.53      -0.59     Missed  -11.6
 Jun. 30 2019  -0.46       -0.45      -0.50     Missed  -10.7
 This summary was machine generated August 6 at 14:25 GMT.  All
figures in US dollars unless otherwise stated